BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,569 | -17.2% | 704 | 0.0% | 0.02% | -16.7% |
| Q2 2023 | $32,074 | -2.1% | 704 | -12.9% | 0.02% | -5.3% |
| Q1 2023 | $32,772 | +7.2% | 808 | +34.7% | 0.02% | 0.0% |
| Q4 2022 | $30,582 | -4.4% | 600 | 0.0% | 0.02% | -9.5% |
| Q3 2022 | $32,000 | -46.7% | 600 | -36.0% | 0.02% | -46.2% |
| Q2 2022 | $60,000 | +27.7% | 938 | +56.3% | 0.04% | +44.4% |
| Q1 2022 | $47,000 | -9.6% | 600 | 0.0% | 0.03% | -10.0% |
| Q4 2021 | $52,000 | +8.3% | 600 | 0.0% | 0.03% | -3.2% |
| Q3 2021 | $48,000 | 0.0% | 600 | 0.0% | 0.03% | -8.8% |
| Q2 2021 | $48,000 | -5.9% | 600 | 0.0% | 0.03% | -10.5% |
| Q1 2021 | $51,000 | +6.2% | 600 | 0.0% | 0.04% | -11.6% |
| Q4 2020 | $48,000 | – | 600 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |